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ABSTRACT

Four methods were developed for simultaneous determination of sulfaquinoxaline-Na and pyrimethamine in their combined
pharmaceutical formulations. The first one was a densitometric method where chloroform-methanol (9: 1, v/v) was the
developing system and the plates were scanned at 254 nm. The obtained spots appeared at Rf 0.64 and 0.35 and determined
in the range of 0.5-10.0 µg/spot and 0.1-10.0 µg/spot for sulfaquinoxaline-Na and pyrimethamine, respectively. Furthermore,
three spectrophotometric methods manipulating ratio spectra namely, ratio difference method, extended ratio subtraction
method coupled with ratio subtraction method and mean centering method were established for the determination of the two
studied drugs in the presence of propylene glycol as a solvent. Linear correlation was found over the concentration range of
2-25 µg mL-1 and 3-15 µg mL-1 for the two drugs, respectively. The proposed methods were successfully applied for analyzing
the cited drugs in their veterinary pharmaceutical formulations. The obtained results were statistically analyzed and found to be
in accordance with those given by a reported method. The validity of the methods was evaluated according to ICH guidelines.
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1. INTRODUCTION
5-(4-Chlorophenyl)-6-ethylpyrimidine-2,4-diamine. It is
a dihydro- folate reductase inhibitor used as antiprotozoal
in the treatment of malaria[1-3]. A combination of both
drugs is used in the poultry industry to effectively combat
coccidiosis[1,2]; Figure 1a.

Sulfaquinoxaline-Na, N 4-Amino-N-quinoxalin-2ylbenzenesulfonamide sodium salt [1,2]. It is a bacteriostatic
sulfonamide used in veterinary medicine as coccidiostat[3]
which acts by interfering with the biosynthesis of folic
acid in bacterial cells[1]; Figure 1a. Pyrimethamine is a

Fig. 1: Chemical structure of (a) sulfaquinoxaline-Na and (b) pyrimethamine
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Several analytical methods have been reported
for the determination of either sulfaquinoxalineNa or pyrimethamine in their pharmaceutical
formulations and/or in biological fluids. The literature
comprises spectrophotometric[4-8], electrochemical[9-12],
biochemical[13-15] and chromatographic techniques namely,
densitometry[16-19], GC[20-22] and HPLC[23-29]. Also, capillary
electrophoresis[30-32] was revealed for sulfaquinoxalineNa determination. It was noticed that the only analytical
methods have been described in the literature for the
simultaneous determination of sulfaquinoxaline-Na and
pyrimethamine in mixture were the first derivative of the
ratio spectra[33,34] and HPLC[35-37].

separately in methanol to be used by the densitometric
method. For the UV-spectrophotometric methods, stock
solutions of the two drugs (0.1 mg mL-1) were prepared by
dissolving 10 mg of sulfaquinoxaline-Na or pyrimethamine
in 100 mL propylene glycol.
2.4. Procedures
2.4.1. Linearity
2.4.1.1. Densitometric method
The TLC plates pre-coated with silica gel 60 F254
(10 × 20 cm) were loaded with ten μL of each solution
at the baseline. The plates were spotted 1 cm apart from
each other and 2 cm apart from the bottom edge. The
chromatographic chamber was pre-saturated for 30
minutes with the mobile phase. Ascending development
process was performed with a mobile phase of chloroform:
methanol (9: 1, v/v) through a distance of 7 cm at room
temperature then the plates were left to dry in air. The spots
finally were scanned at 254 nm and the areas under the
peaks were recorded against each drug concentration and
the regression equations were calculated.

The aim of the present study is to develop simple,
sensitive, selective and accurate densitometric and
UV-spectrophotometric methods for the simultaneous
determination of sulfaquinoxaline-Na and pyrimethamine
in their pharmaceutical formulations.
2. EXPERIMENTAL
2.1. Instruments
•

Densitometer model 3; equipped with WinCats
software, Camag TLC scanner 3, Camag lincomat
5 autosampler.

•

UV-Vis
Japan).

spectrophotometer

(Shimadzu

•

Thin layer chromatographic plates pre-coated with
silica gel 60 F254, 10x20 cm (Merck, Germany).

2.4.1.2. Spectrophotometric methods
Accurately measured aliquots of sulfaquinoxalineNa or pyrimethamine standard solutions in propylene
glycol (0.1 mg mL-1) equivalent to 0.02-0.25 mg or
0.03-0.15 mg, respectively; were separately dissolved in
10-mL propylene glycol. The prepared solutions were
scanned over the range of 200-400 nm and the zero-order
spectra were stored in the computer. The ratio spectra of
sulfaquinoxaline-Na were calculated using 10 µg mL-1
pyrimethamine as a divisor in case of the ratio difference
and the extended ratio subtraction methods or 3 µg mL-1
pyrimethamine for the mean centering method. Whereas
pyrimethamine ratio spectra were obtained upon dividing
its spectra by 20 µg mL-1 sulfaquinoxaline-Na to be used
by all the proposed methods.

1601,

2.2. Materials and Reagents
•

Pure sulfaquinoxaline-Na, B. N. BL130602, was
kindly supplied by Unipharma Company, Egypt
with purity of 99.5% as referred by the supplier.

•

Pure pyrimethamine, B.N. 120070108, was kindly
supplied by Copad Pharma, Egypt; 99.8% purity
as referred by the supplier.

•

Sodicoc-oral solution (1 Liter); B.N. 0152163,
labeled to contain 46.6 mg of sulfaquinoxaline-Na
and 15 mg of pyrimethamine per mL, the product
of Biovet, Egypt; was purchased from a local
market.

•

2.4.1.2.1. Ratio difference (RD) method
The calibration curves of the two drugs were
constructed by plotting the difference between the
amplitudes of the obtained ratio spectra at 251 and 297
nm for sulfaquinoxaline-Na or between 297 and 280
nm for pyrimethamine versus the corresponding drug
concentration. Then, the regression equation of each drug
was computed.

Thiamincox-oral solution (1 Liter); B.N. 60450,
labeled to contain 34.88 mg of sulfaquinoxalineNa and 9.8 mg of pyrimethamine per mL, the
product of Medizen Pharmaceutical Industry,
Egypt; was purchased from a local market.

•

Methanol, HPLC grade (Scharlau chemie, Spain).

•

Chloroform, HPLC grade (Honil Limited, London,
UK).

•

Propylene glycol, (Adwic. Cairo, Egypt).

2.4.1.2.2. Extended ratio subtraction (EXRS) coupled
with ratio subtraction (RS) method
The absorbance of the zero-order spectra of
sulfaquinoxaline-Na at 250 and 267 nm or those of
pyrimethamine at 288 nm were linearly recorded against
the corresponding concentration from which the regression
equations were deduced.

2.3. Standard solutions

2.4.1.2.3. Mean centering (MC) method

Five mg mL-1 solution of sulfaquinoxaline-Na and
two mg mL-1 solution of pyrimethamine were prepared

From the stored data, the ratio spectra were firstly mean
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spectrum was multiplied by 10 µg mL-1 pyrimethamine'
where sulfaquinoxaline-Na zero-order spectrum would
result. Sulfaquinoxaline-Na concentration in each mixture
was calculated at 250 and 267 nm using its corresponding
regression equations.

centered using MATLAB R2017b software. Subsequently,
the amplitude of the resultant mean centered peaks was
measured at 223 and 299 nm and plotted against the
corresponding sulfaquinoxaline-Na concentrations to
get its regression equations. The same procedure was
followed for pyrimethamine to be quantified and the
regression equation was obtained from the calibration
curve representing the peak amplitude at 223 nm against
pyrimethamine concentrations.

2.4.3. Application to pharmaceutical formulations
The contents of five Sodicoc-oral solutions were
thoroughly mixed. A volume equivalent to 466 mg
sulfaquinoxaline-Na and 150 mg pyrimethamine was
transferred into 100-mL volumetric flask and volume was
completed with methanol to obtain a clear solution labeled
to contain 4.66 mg mL-1 sulfaquinoxaline-Na and 1.50
mg mL-1 pyrimethamine to be analyzed by the proposed
densitometric method. For the spectrophotometric
methods, five mL of Sodicoc solution equivalent to 23.30
mg sulfaquinoxaline-Na and 7.50 mg pyrimethamine were
dissolved in 100-mL propylene glycol to prepare a solution
claimed to contain 0.233 mg mL-1 sulfaquinoxaline-Na
and 0.075 mg mL-1 pyrimethamine.

2.4.2. Assay of laboratory prepared mixtures of the two
drugs
2.4.2.1. Densitometric method
Into a set of 10-mL volumetric flasks, aliquots of standard
sulfaquinoxaline-Na solution (5 mg mL-1) equivalent to
0.5-10.0 mg drug were mixed with different volumes of
standard pyrimethamine (2 mg mL-1) containing 0.1-10.0
mg pure drug. Volumes were completed to the mark with
methanol and the prepared mixtures were then analyzed by
densitometry as described under “2.4.1. Linearity”.

Similarly, the contents of five Thiamincox-oral
solutions were treated as previously mentioned to obtain
two solutions; the first labeled to contain 3.488 mg mL-1
sulfaquinoxaline-Na and 0.98 mg mL-1 pyrimethamine
in methanol while the other claimed to contain 0.1744
mg mL-1 sulfaquinoxaline-Na and 0.049 mg mL-1
pyrimethamine in propylene glycol. These two sample
solutions were analyzed for assay determination by the
suggested densitometric and spectrophotometric methods,
respectively.

2.4.2.2. Spectrophotometric methods
Aliquots of standard drugs solutions (0.1 mg mL-1)
equivalent to 0.02-0.25 mg sulfaquinoxaline-Na and 0.030.15 mg pyrimethamine were mixed in a series of 10-mL
volumetric flasks. Volumes were completed with propylene
glycol and the zero-order spectra of the mixtures were
recorded at 200–400 nm. The ratio spectra of the laboratory
prepared mixtures were obtained following the abovementioned procedures detailed under “2.4.1. Linearity”.
The concentration of each drug was calculated by
substitution in the corresponding regression equation after
applying the corresponding manipulating steps described
under “2.4.1. Linearity” for the ratio difference and mean
centering methods. However, the following procedures
should be applied in case of the ratio subtraction and the
extended ratio subtraction methods:

For each proposed method, the details under “2.4.1.
Linearity” and “2.4.2. Assay of laboratory prepared
mixtures of the two drugs” were followed and the
concentration of each drug was calculated from the
corresponding regression equation.
Upon carrying out the standard addition technique,
either Sodicoc solution or Thiamincox solution was mixed
well with different portions of pure sulfaquinoxaline-Na
and pyrimethamine solutions before proceeding in the
above-mentioned procedures.

On one hand, the ratio subtraction method was
performed for pyrimethamine estimation. A plateau
region (205–215 nm) was observed in the ratio spectra of
the laboratory prepared mixtures. The amplitude of this
plateau region was recorded and then subtracted from
those laboratory prepared mixtures ratio spectra. Then,
upon multiplying the obtained spectra by 20 µg mL-1
sulfaquinoxaline-Na', pyrimethamine zero-order spectrum
was obtained and accordingly its concentration in each
mixture was calculated from the corresponding regression
equation at 288 nm.

3. RESULTS AND DISCUSSION
3.1. Densitometric method
Literature survey revealed the lack of any densitometric
method for sulfaquinoxaline-Na determination either alone
or in the presence of pyrimethamine. Several developing
systems with different ratios were tried, such as ethyl
acetate-dichloromethane (8:2, v/v), ethyl acetate-methanol
(9:1, v/v), chloroform-ethyl acetate-methanol (5:5:1, v/v/v),
chloroform-toluene-methanol (6:5:3, v/v/v); none of them
fulfill the purpose. Best resolution of sulfaquinoxaline-Na
and pyrimethamine was achieved using a mobile phase
of chloroform- methanol (9: 1, v/v) where the Rf values
were found to be 0.64 and 0.35, respectively. Based on this
difference in Rf values, the chromatogram of the two drugs
were measured densitometrically at 254 nm; Figure 2.

On the other hand, sulfaquinoxaline-Na could be
estimated by applying the extended ratio subtraction.
Firstly, the constant value at the plateau area should be
calculated. It was done by dividing the spectrum of standard
pyrimethamine of the same concentration that is found in
the laboratory prepared mixture by the selected devisor 10
µg mL-1 pyrimethamine'. Again, this plateau value would
be subtracted from the corresponding ratio spectrum of
the laboratory prepared mixture. Finally, the obtained
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Fig. 2: Densitometric chromatogram of (1) sulfaquinoxaline-Na (0.5 - 10
µg / spot) and (2) pyrimethamine (0.1 - 10 µg / spot).

3.2. Spectrophotometric methods
It was noticed that almost the commercially available
veterinary formulations containing sulfaquinoxaline-Na
and pyrimethamine combination had been formulated
using propylene glycol as a solvent. Propylene glycol has
an absorption band at 240 nm where high interference with
the already overlapped spectra of the two cited drugs was
observed. A problem that had hindered their quality control
analysis spectrophotometrically; Figures 3 and 4. Another
problem was the presence of the excipients N-methyl
pyrrolidone and dimethyl formamide in Sodicoc solution
which absorb at 217 nm where additional overlap was
found. Consequently, three spectrophotometric methods
manipulating ratio spectra were developed namely, ratio
difference method, extended ratio subtraction coupled
with ratio subtraction method and mean centering method
where propylene glycol was the solvent. It is noteworthy to
mention that all the established methods could be applied
successfully to solve the spectral overlap of the two cited
drugs in the presence of propylene glycol together with the
above-mentioned excipients beyond the mean centering
method that failed to reveal the excipients spectral overlap.

Fig. 4: Absorption spectra of (1) sulfaquinoxaline-Na 10 µg mL-1 and (2)
pyrimethamine 10 µg mL-1 in propylene glycol.

In addition, there are two common factors should
be taken into consideration when applying methods
manipulating ratio spectra. The first one is the choice
of a divisor which should provide minimal noise with
maximum sensitivity. The second one is the choice of the
wavelengths that exhibit different amplitudes in the ratio
spectrum besides showing a linear relationship at each
wavelength[38, 39].
3.2.1. Ratio difference (RD) method
This method depends on measuring the difference in
amplitudes in the ratio spectra at which linear correlation
was observed. Likewise, the devisor concentration
yielding a superior signal to noise ratio was studied. On
these bases, sulfaquinoxaline-Na was determined using 10
µg mL-1 pyrimethamine as a divisor where the selected
amplitudes were at 251 and 297 nm. Similarly, the selected
wavelengths for the estimation of pyrimethamine using
standard sulfaquinoxaline-Na (20 µg mL-1) as a divisor
were 297 and 280 nm; Figures 5 and 6.

Fig. 5: Ratio spectra of sulfaquinoxaline-Na (2-25 µg mL-1) using 10 µg
mL-1 pyrimethamine as a devisor.

Fig.3: Absorption spectrum of propylene glycol against ethanol as a
blank.
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Fig. 7: Mean centered ratio spectra of sulfaquinoxaline- Na
(2-25 µg mL-1) using 3 µg mL-1 pyrimethamine as a devisor.

Fig. 6: Ratio spectra of pyrimethamine (3-15 µg mL-1) using 20 µg mL-1
sulfaquinoxaline-Na as a devisor.

3.2.2. Extended ratio subtraction (EXRS) method coupled
with ratio subtraction (RS) method
The two methods are integral due to their ability to
evaluate the two target compounds in the mixture. Both
methods are based on subtraction of the plateau values
from the ratio spectrum of each drug. Then, the obtained
spectrum would be multiplied by the corresponding
devisor to be converted into its original zero-order one
which is directly used for the drug determination from its
corresponding regression equation.
3.2.3. Mean centering (MC) method
This method merely depended on mean centering of
ratio spectra. Different concentrations of pyrimethamine
were tried as a divisor for sulfaquinoxaline-Na
determination, and only pyrimethamine 3 µg mL-1 was
found to be the most suitable one as it gave higher and welldefined analytical signals of sulfaquinoxaline-Na. While
pyrimethamine determination was conducted using 20
µg mL-1 sulfaquinoxaline-Na as a divisor which provide
maximum selectivity. Mean-centering of the ratio spectra
was obtained in the wavelength range of 200-350 nm for
sulfaquinoxaline-Na or 200-400 nm for pyrimethamine;
Figures 7 and 8. The concentration of sulfaquinoxalineNa and pyrimethamine was determined by measuring
the mean centered peak amplitude at 223 and 299 nm for
the former and at 223 nm for the latter. Unfortunately,
pyrimethamine could not be determined at 298 nm due to
unreliable results.

Fig. 8: Mean centered ratio spectra of pyrimethamine (3-15 µg mL-1)
using 20 µg mL-1 sulfaquinoxaline-Na as a devisor.

3.3. Method validation
The proposed methods were validated according to
ICH guidelines[40].
3.3.1. Linearity
The obtained standard curves of the peak areas of the
separated spots or the response and the corresponding
drug concentration were linear in the ranges of, 0.510.0 μg/spot and 0.1-10.0 μg/spot for the densitometric
method and 2-25 μg mL-1 and 3-15 μg mL-1 for the
spectrophotometric methods regarding sulfaquinoxalineNa and pyrimethamine, respectively. The regression data
were calculated and presented in Table 1.
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pyrrolidone and dimethyl formamide as excipients which
are not contained in Thiamincox solution. Nevertheless,
sulfaquinoxaline-Na could be determined in Sodicoc
solution at the other wavelength 299 nm.

3.3.2. Accuracy and precision
The repeatability and the reproducibility of the proposed
methods was assured by triplicate analysis of three different
concentrations of each drug covering its specified linearity
range, within one day and at three different days over a
period of two months. The obtained accuracies ranges were
99.62-100.74% and 99.78-100.50% with RSD% amounted
to be 0.17-1.70 and 0.19-1.67 for sulfaquinoxaline-Na and
pyrimethamine, respectively; Table 1.

Validity of the proposed methods was further assessed
by applying the standard addition technique where the
good recoveries of pure drug samples suggest satisfactory
accuracy, Table 3. These results were statistically[41]
compared with those obtained from a reported method
which is a UV- measurements for the first derivative of the
ratio spectra of sulfaquinoxaline-Na at 241 and 271 nm and
pyrimethamine at 290 and 304 nm[33]. As shown in Table
3, calculated t- and F-values were less than theoretical
ones, indicating that there was no significant difference
between the proposed and reported methods. However,
the proposed methods were found to be more selective,
so that the quantitative estimation of sulfaquinoxaline-Na
and pyrimethamine in their combined formulations could
be carried out successfully without interference from
excipients and additives.

3.3.3. Selectivity
Sulfaquinoxaline-Na was mixed with pyrimethamine in
different ratios (1:2, 1:1, 2:1 and 3:1, respectively) and the
prepared mixtures were analyzed by the densitometric and
spectrophotometric methods. Simultaneous determination
of the two drugs without any interference was done. Thus,
the established methods were proved to be selective as
indicated by recoveries of 99.12 - 100.65% ± 0.77-1.35
and 98.77 - 100.77% ± 0.71-1.18 for sulfaquinoxaline-Na
and pyrimethamine, respectively; Table 2.
The selectivity of the proposed methods was further
evaluated by analyzing the studied drugs in two of their
veterinary pharmaceutical formulations; Sodicoc and
Thiamincox oral solutions. Satisfactory results had
confirmed that both drugs could be simultaneously
determined by all the proposed methods without
interference from excipients and additives except the mean
centering one, Table 3.

3.3.4. Stability of standard solutions
The stability of the methanolic solutions of
sulfaquinoxaline-Na (5 mg mL-1) and pyrimethamine
(2 mg mL-1) were evaluated by the densitometric method.
This was carried out through storing on laboratory bench
and in the refrigerator at 4°C. The solutions were found to
be stable for two weeks either at room temperature or in
refrigerator. While the stability of the standard solutions
of both drugs in propylene glycol (0.1 mg mL-1) were
evaluated by the spectrophotometric methods and found to
be stable for more than one month at room temperature or
in refrigerator.

Although the mean centering method was employed
successfully for determining the two drugs in Thiamincox
solution, unfortunately, neither sulfaquinoxaline-Na nor
pyrimethamine could be quantitatively estimated at 223
nm in Sodicoc solution due to the presence of N-methyl

40

41

0.57-1.60

1.10-1.70

Intraday

100.74 ± 0.75

Interday

(RSD%, n=9)

Precision

(R%± S.D.)

Accuracy

coefficient

0.9997

288.188

S.D. of residual

Correlation

4751.91 ± 194.801

3817.81 ± 35.153

0.5 – 10.0 µg/spot

Densitometric method

Intercept ± S.D.

Slope ± S.D.

Parameters

Regression

linearity range

Parameters

0.68 – 1.25

0.17 – 1.30

100.65 ± 1.21

0.9999

0.008

0.001 ± 0.006

0.081 ± 0.000

0.43 – 1.06

0.26 – 0.73

99.90 ± 0.54

0.9998

0.009

-0.059 ± 0.007

0.069 ± 0.000

0.94 – 1.62

0.64 – 1.48

100.06 ± 0.42

0.9998

0.033

-0.186 ± 0.026

0.216 ± 0.002

2 – 25 µg mL-1

at 251-297 nm

at 250 nm

at 267 nm

Ratio difference

Extended ratio subtraction

0.92 – 1.48

0.46 – 1.10

100.30 ± 1.44

0.9998

0.103

-0.025 ± 0.081

0.709 ± 0.005

0.90 – 1.10

0.30 – 0.97

99.62 ± 0.84

0.9998

0.083

-0.324 ± 0.065

0.593 ± 0.004

at 299 nm

Mean centering method
at 223 nm

Spectrophotometric methods

Sulfaquinoxaline-Na

0.80 – 1.52

0.73 – 1.67

100.20 ± 0.58

0.9997

206.422

28.442

971.51 ±

136.171

2917.12 ±

µg/spot

0.1 – 10.0

method

Densitometric

0.43 – 0.92

0.28 – 1.42

99.91 ± 0.46

0.9998

0.003

0.004 ± 0.003

0.036 ± 0.000

at 288 nm

0.86 – 1.19

0.63 – 0.99

100.50 ± 0.22

0.9999

0.001

-0.011± 0.001

0.031 ± 0.000

3 – 15 µg mL-1

at 297-280 nm

Ratio difference

0.49 – 0.89

0.19 – 1.20

99.78 ± 0.69

0.9998

0.073

0.034 ± 0.006

0.090 ± 0.001

at 223 nm

method

Mean centering

Spectrophotometric methods

Pyrimethamine

Ratio subtraction

Table 1: Regression parameters and assay validation results for the determination of sulfaquinoxaline-Na and pyrimethamine by the proposed methods
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5

5

10

8

5

3

9

10

5

24

18

9

3

Mean% ± SD

Pyrimethamine

5

Na

Sulfaquinoxaline-

Drugs ratio

42
99.59 ± 1.33

100.50

98.24

-

-

99.26

101.40

98.57

Na

Sulfaquinoxaline-

Recovery % of

100.77 ± 0.97

100.36

101.95

-

-

101.17

99.35

101.03

Pyrimethamine

Recovery % of

Densitometric method
at 267 nm

100.07 ± 1.35

98.18

100.83

101.69

99.07

99.11

100.05

101.59

± 1.17

100.65

100.92

101.0

101.88

101.91

100.43

99.64

98.70

Sulfaquinoxaline-Na

Recovery % of

at 250 nm

99.43 ± 1.08

98.52

99.26

100.11

101.46

98.67

99.56

98.44

Pyrimethamine

Recovery % of

at 288 nm

with Ratio subtraction

Extended ratio subtraction coupled

Table 2: Determination of sulfaquinoxaline-Na and pyrimethamine in mixtures using the proposed methods

99.12 ± 0.77

98.09

100.42

98.91

99.40

98.41

99.55

99.06

Na

Sulfaquinoxaline-

Recovery % of

at 251-297 nm

99.99 ± 1.18

100.47

98.80

99.15

98.73

99.90

101.77

101.11

Pyrimethamine

Recovery % of

at 297-280 nm

Ratio difference

Spectrophotometric methods

at 299 nm

100.04 ± 1.23

99.23

100.99

101.23

101.47

100.09

98.32

98.96

0.87

99.77 ±

98.43

99.28

100.30

100.17

101.14

99.61

99.42

Sulfaquinoxaline-Na

Recovery % of

at 223 nm

98.77 ± 0.71

98.19

98.60

98.11

99.00

98.11

99.85

99.51

Pyrimethamine

Recovery % of

at 223 nm

Mean centering method
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Table 3: Statistical analysis of determination of sulfaquinoxaline-Na and pyrimethamine in their pharmaceutical formulations by the proposed methods in comparison with the reported method[33]
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4. CONCLUSION

13. N.J. Lee, C.K. Holtzapple, M.T. Muldoon, S.S.
Deshpande, L.H. Stanker, Food Agr. Immunol. 13
(1) (2001) 5-17.

Two
techniques;
densitometry
and
UVspectrophotometry had been developed for the
determination of sulfaquinoxaline-Na together with
pyrimethamine in their veterinary pharmaceutical
formulations. The densitometric method, as a separative
one, is very sensitive and consumes minimum amount of
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